A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS ...
The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of ...
Precision medicine in endometrial cancer emphasizes molecular drivers, challenging traditional histopathologic approaches and necessitating careful biomarker selection. Next-generation sequencing ...
FT. MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will present three studies at the European Society for Medical Oncology (ESMO) Congress ...
Hello. This is Mark Kris, from Sloan Kettering, continuing my discussion about the increasing precision of lung cancer therapies and the need for additional testing beyond our routine next-generation ...
Prospective real world data evaluation of clinical outcomes in metastatic hormone sensitive prostate cancer (MHSPC) patients treated as part of triplet therapy with darolutamide: UK multicenter ...
Twist Bioscience's Q1 growth was modest, due in large part to an air pocket in demand caused by a large NGS customer. Read ...
Children's Hospital Los Angeles (CHLA) and Thermo Fisher Scientific have agreed to develop a next-generation sequencing (NGS)-based panel designed specifically for pediatric cancer research. The assay ...
“Emerging technologies leveraging ctDNA and NGS are increasing our ability to identify cancers in high-risk patients, which was previously beyond reach,” said Dr. Nathan Montgomery, Vice President of ...
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will present four abstracts at the Association for Molecular Pathology (AMP) 2024 Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results